Beam Therapeutics Inc Total Liabilities
Beam Therapeutics Inc total liabilities. Based on the latest financial reports, Beam Therapeutics Inc (BEAM) has total liabilities worth $319.19 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Beam Therapeutics Inc (BEAM) liquidity interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Beam Therapeutics Inc (2017–2025)
Total liabilities of Beam Therapeutics Inc from 2017 to 2025. This chart illustrates how Beam Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Beam Therapeutics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Beam Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Beam Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Go Digit General Insurance Ltd
NSE:GODIGIT
|
India | Rs-46.86 Billion |
|
Workiva Inc
NYSE:WK
|
USA | $1.44 Billion |
|
Visual Photonics Epitaxy Co Ltd
TW:2455
|
Taiwan | NT$2.02 Billion |
|
Talos Energy
NYSE:TALO
|
USA | $3.40 Billion |
|
Shurgard Self Storage SA
BR:SHUR
|
Belgium | €2.75 Billion |
|
Guangzhou Great Power Energy&Technology Co Ltd
SHE:300438
|
China | CN¥17.66 Billion |
|
Comet Holding AG
SW:COTN
|
Switzerland | CHF199.23 Million |
|
Hubei Xinyangfeng Fertilizer Co Ltd
SHE:000902
|
China | CN¥7.68 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Beam Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Beam Therapeutics Inc total assets.
Liquidity & Leverage Metrics
Beam Therapeutics Inc Total Liabilities Ratios Explained
Beam Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beam Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beam Therapeutics Inc (2017–2025)
The table below shows the annual total liabilities of Beam Therapeutics Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $242.82 Million | -34.42% |
| 2024-12-31 | $370.28 Million | -22.60% |
| 2023-12-31 | $478.38 Million | -21.35% |
| 2022-12-31 | $608.24 Million | -6.09% |
| 2021-12-31 | $647.72 Million | +214.25% |
| 2020-12-31 | $206.12 Million | +273.71% |
| 2019-12-31 | $55.15 Million | +67.21% |
| 2018-12-31 | $32.98 Million | +400.90% |
| 2017-12-31 | $6.58 Million | -- |
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targ… Read more